Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: lysosphingolipid receptor agonists - Amgen/EPIX

Drug Profile

Research programme: lysosphingolipid receptor agonists - Amgen/EPIX

Alternative Names: AMG 277; PRX-13038; S1P1 agonists - EPIX

Latest Information Update: 07 Oct 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EPIX Pharmaceuticals
  • Developer Amgen; EPIX Pharmaceuticals
  • Class
  • Mechanism of Action Lysosphingolipid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Autoimmune disorders; Cancer

Most Recent Events

  • 06 Oct 2011 This programme will be offered for sale on December 8, 2011 ,,
  • 01 Oct 2009 Discontinued - Preclinical for Autoimmune disorders in USA (PO)
  • 28 Mar 2008 Research programme is still in preclinical trials for Autoimmune disorders in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top